Novo Seeds pours more money into Danish diabetes patch
Danish medtech company Reapplix has raised millions from a group of prominent investors, who are already committing to new, larger investments to bring the company's lead product all the way to the European market.
BY STEFAN SINGH KAILAY
The great relationship between the Danish medtech company Reapplix and its investors continues as the firm has secured EUR 2.7 million (USD 3 million) in new funding from existing contributors.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Reapplix wins patent in US and Japan
For abonnenter
